University of Pennsylvania · BiologyKRAS Targeted T Cell Therapy Group
Beatriz M. Carreno · Philadelphia, Pennsylvania
Research Focus
Dr. Beatriz M. Carreno's lab focuses on developing advanced T cell therapies for solid tumors that have mutations in the KRAS gene, which are common in many cancers. The team works on engineering T cells to specifically target and attack these cancer cells while overcoming hurdles posed by the tumor environment that typically dampen T cell activity. Their ultimate goal is to create a new therapy that can significantly improve outcomes for patients with these difficult-to-treat tumors.
T cell therapyKRAS mutationstumor microenvironmentgene editingcell exhaustionimmunotherapyclinical trialspersonalized medicineadoptive cell therapy
Research Aims
3AIM 01Develop gene-modified T cells to specifically target KRAS mutations in tumors.
AIM 02Evaluate the effectiveness of CD4+ T cells in supporting CD8+ T cell responses.
AIM 03Conduct a clinical trial to assess the safety and effectiveness of the engineered T cell therapies.
Skills the Lab Values
T cell receptor engineeringCRISPR/Cas9cell culture techniquesclinical trial designbiomarker identificationflow cytometrymolecular pathologyimmune profilingsingle cell technologies
Output against the department
Publications148top 46% of dept.477th of 1,033
this lab
most publishedleast published
Citations21ktop 19% of dept.196th of 1,033
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.